Metraipolis › archive › dc_6beaaaa3578e

Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis — Europe PMC PMID:42120997

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42120997
DOI
10.1002/edm2.70238
License (as archived)
solo-consultazione
Archived
2026-11-02T22:43:18.752Z
SHA-256 of the archived text
aea5c16c6c1856922a387410eddc3f65718a2507e940b15fbadcb2328358d5f1
Stable URL of this page
https://metraipolis.com/documento/dc_6beaaaa3578e

How to cite

Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis — Europe PMC PMID:42120997 — Europe PMC (en), https://europepmc.org/article/MED/42120997 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6beaaaa3578e (Metraipolis archive dc_6beaaaa3578e, sha256 aea5c16c6c1856922a387410eddc3f65718a2507e940b15fbadcb2328358d5f1)
BibTeX
@misc{dc6beaaaa3578e,
  title = {Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis — Europe PMC PMID:42120997},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42120997},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6beaaaa3578e; sha256 aea5c16c6c1856922a387410eddc3f65718a2507e940b15fbadcb2328358d5f1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42120997. Agents can read the archived copy with the MCP tool read_document.